The molecular mechanisms driving prostate cancer have been intensively investigated, and involve hormone-driven signalling pathways, “classical” oncogenes including ERG and MYC, and tumour suppressors like PTEN [3, 4]. The gene discussed is PTEN; the disease is prostate carcinoma.